Article

Sightpath Medical: New name for MSS and LaserVision

Minneapolis-Sightpath Medical is the new name encompassing MSS and LaserVision-a mobile access cataract and glaucoma surgical services provider and product distributor, and a mobile access refractive surgical services business, respectively.

Minneapolis-Sightpath Medical is the new name encompassing MSS and LaserVision-a mobile-access cataract and glaucoma surgical services provider and product distributor, and a mobile-access refractive surgical services business, respectively. Operating as divisions of Sightpath Medical, a wholly owned subsidiary of TLC Vision Corp., both companies’ products and services will be combined under the new name.

“Our new name helps emphasize our dedication to helping clients create the ‘best path to sight’ for their patients,” said Jim Tiffany, president of Sightpath Medical. “By providing our doctors and eye-care facility partners with leading ophthalmic technologies and innovative, customized solutions, we create paths for them to develop the service offerings they want.”

MSS was founded in Minneapolis in 1991 and offers cataract and glaucoma services throughout 41 states, serving more than 500 customers.

LaserVision was founded in St. Louis and moved to Minneapolis in 2007. It currently markets to more than 600 customers who offer refractive services in 48 states. It provides access to transportable and fixed-based excimer lasers, femtosecond lasers, wavefront analyzers, and related surgical equipment and personnel.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
© 2025 MJH Life Sciences

All rights reserved.